Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

This study tests a new type of immune cell therapy — CAR-NK cells derived from umbilical cord blood — in people with T-cell lymphoma that has relapsed or stopped responding to treatment. CAR-NK cells are specially engineered natural killer immune cells designed to attack specific markers on cancer cells. **You may be eligible if...** - You are 18 to 75 years old - You have confirmed relapsed or refractory peripheral T-cell lymphoma - Your cancer has a specific target marker (TRBC1/2 positive, at least 20%) confirmed by tissue testing - You have failed at least one prior line of treatment - Your life expectancy is at least 12 weeks - Your organ function is adequate **You may NOT be eligible if...** - You have active serious infections - You have had a prior allogeneic stem cell transplant within 6 months - You have uncontrolled brain involvement by lymphoma - You have significant organ dysfunction Talk to your doctor to see if this trial is right for you.